Ampel Biosolutions
US-based precision medicine firm offering LDTs for disease prediction, molecular pathways, and drug options.
Founded
2013US-based precision medicine firm offering LDTs for disease prediction, molecular pathways, and drug options.
Founded in Charlottesville, United States, Ampel Biosolutions is a precision medicine company dedicated to revolutionizing the management of autoimmune and inflammatory diseases. Their core mission is to provide personalized, predictive care through advanced RNA analytics and AI-driven insights. Ampel offers Laboratory Developed Tests (LDTs) that predict disease status, identify molecular pathways, and suggest optimal drug options. Their market focus includes conditions such as lupus, dermatology issues, nephrology, fibromyalgia, cardiology, arthritis, and infections.
Notable figures affiliated with Ampel Biosolutions include a distinguished executive team and advisory group comprising experts in precision medicine and AI. The company has made significant strides in the healthcare sector by publishing influential research papers and forming strategic partnerships. Ampel's innovative approach has garnered attention for its potential to transform patient care and improve outcomes through tailored treatment strategies.
Companies similar to Ampel Biosolutions include Amprion, Ariel Precision Medicine, Amplified Sciences and HI-Bio.
Ampel Biosolutions was founded in 2013.
Ampel Biosolutions' headquarters is located in Charlottesville, VA, US.
Ampel Biosolutions' most recent funding round was for $1.8M (USD) in July 2023.
As of Jul 6, 2023, Ampel Biosolutions has disclosed funding of $14.3M (USD). Undisclosed round amounts are excluded.
Ampel Biosolutions has 29 employees as of Feb 4, 2024.
HI-Bio
hibio.com
